25/02/2026
Welcome back to the DIMSS Digest, where we break down a high-impact clinical trial or guideline into digestible and relevant teaching points — helping you build the skills to read, analyze, and apply real research to real patients.
This week: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
A new NEJM original article explores the clinical benefit of Trastuzumab Deruxtecan as a postneoadjuvant therapy for HER2-Positive Breast Cancer compared to Trastuzumab Emtansine, which is the current standard treatment, and investigate which therapy increases the likelihood of invasive disease-free survival post treatment. Check out our new Google Drive for the detailed breakdown of this trial, written by Education Officer Raghav.
Stay tuned every two weeks as we continue breaking down the studies that shape internal medicine — so that you can stay informed for your next rounds
Source: Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. New England Journal of Medicine. 2025 Dec 10;
Illustration: Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy. 2021 Oct;Volume 12:103–14.